SK Capital to Invest in Swixx BioPharma AG, Valuation Exceeds EUR €1.5 Billion

SK Capital Partners will invest in Swixx BioPharma AG to boost the company's growth and global expansion. The investment values Swixx, a leader in pharmaceutical commercialization services for underserved markets, at over EUR €1.5 billion. Mérieux Equity Partners also invests in healthcare companies.